Unlocking the potential of immuno-oncology
Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.
Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system.
Unlocking the potential of IO
Watch our video and discover how BO-112 is unlocking the potential of IO.